



Abbott

# BINAXNOW<sup>TM</sup> INFLUENZA A & B CARD 2, WITH DIGIVAL<sup>TM</sup>

This latest technology is brought to you by Abbott, a market leader in US rapid point-of-care influenza diagnostic assays.

The BinaxNOW<sup>TM</sup> Influenza A & B Card 2 assay is the latest advancement in lateral flow technology. It is a reformulated version of the original market leading BinaxNOW Influenza assay, which in conjunction with the innovative DIGIVAL, offers improved performance for rapid influenza testing.



# BinaxNOW™ Influenza A & B Card 2, with DIGIVAL™

## FEATURES & BENEFITS

### Flexible sample types

Option of a Nasal Swab or Nasopharyngeal Swab sample type.

### Rapid results

Control of a connected instrument with the speed of a rapid lateral flow assay.

### Objective results

Eliminate operator subjectivity and establish consistency in the reading.

### Enhanced quality control

Quality Control module and a QC lockout feature to ensure quality controls are tested.

### Easy-to-use

Straight forward rapid assay procedure, followed by DIGIVAL interpretation.

### Workflow flexibility

Read Now Mode or Walk Away Mode to suit your workflow and throughput.

### Throughput

Interpret up to 30 assays per hour\*

### Result management

Capture results on DIGIVAL, print them or share them through our Bi-Directional Connectivity to LIMS/Middleware via the POCT1-A protocol.


## TEST PROCEDURE

1 Elute swab specimen.




2

Add entire contents of the 100 ul pipette in a continuous flow to the top, white sample pad.



3

Close and securely seal the card by pressing the right edge of the test card.



4


Interpret results on DIGIVAL with either

#### • Read Now Mode:

After 15 minute incubation, insert the test card and close drawer for interpretation.

#### • Walk Away Mode:

After inoculation, insert the test card and close drawer. DIGIVAL will automatically interpret result at the read time.



## CLIA WAIVER PERFORMANCE

### BINAXNOW™ INFLUENZA A & B CARD 2 – FLU A

	COMPARATOR METHOD*		
	POSITIVE	NEGATIVE	TOTAL
Positive	141	23	164
Negative	21	508	529
Total	162	531	693
PPA: 87.0% (141/162) 95% CI: (81.0%-91.4%)			
NPA: 95.7% (508/531) 95% CI: (93.6%-97.1%)			

### BINAXNOW™ INFLUENZA A & B CARD 2 – FLU B

	COMPARATOR METHOD*		
	POSITIVE	NEGATIVE	TOTAL
Positive	116	3	119
Negative	6	568	574
Total	122	571	693
PPA: 95.1% (116/122) 95% CI: (89.7%-97.7%)			
NPA: 99.5% (568/571) 95% CI: (98.5%-99.8%)			

\* An FDA cleared influenza real-time Polymerase Chain Reaction (RT-PCR) assay was utilized as the comparator method for this study.

## ORDERING INFORMATION

DESCRIPTION	ORDER NO.
DIGIVAL BinaxNOW™ Complete Kit	LFR-124
<b>Complete Kit Contents</b>	
DIGIVAL	LFR-024
Barcode Scanner	L22XWU1-200
BinaxNOW™ Tray Pack	LFR-004
Calibration Check Card Pack	LFR-003
USB Drive	EQ004003
<b>Optional Equipment</b>	
MarTEL Thermal Printer	MCP1810395
Replacement Printer Paper	GP15
<b>Available Assays</b>	
BinaxNOW™ Influenza A & B Card 2 22 tests per kit	575-000

VISIT ABBOTT.COM/POCT TODAY.

\*Throughput calculated based on a 2 minute read time per assay in Read Now mode (15 second read time per assay once inserted into instrument, 45 second step for result saving/printing/upload and removal of assay from instrument, and 1 min instrument setup time for next assay). Does not include 15 minute incubation time.

© 2019 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. IDDM233495 120003559-05 05/19

